Navigation Links
Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet

NEW YORK, June 14, 2013 /PRNewswire/ -- The law firm of Rheingold, Valet, Rheingold, McCartney & Giuffra LLP has just commenced what is believed to be the first suit in New York for the development of pancreatic cancer in the user of two common anti-diabetic drugs, Byetta and Janumet (also known as Januvia).  The suit, by Staten Island resident Robert Cataletto, was filed on June 14, 2013 Cataletto v. Amylin Pharmaceuticals, LLC, et al., E.D.N.Y. CV 13-3411.

Mr. Cataletto received prescriptions from the doctor attending to his adult diabetes condition in the period from 2009 to 2012 for Byetta and Janumet.  Byetta, manufactured by Merck, Inc., has been on the market since 2005 and is known as a glucagen-like peptide.  It treats diabetes by preventing a build- up of sugar in the body. 

Junuvia is made by Amylin Pharmaceuticals LLC, a company recently bought by Bristol Myers Squibb Co.  First marketed in 2007, it in the category of a dipeptidyl-peptidase-4 drug, which also reduces blood glucose levels.  When combined with an older drug, metformin, the drug is known as Janumet.  The broader category for the drugs involved in this law suit is known as "incretins."

The complaint which was just filed alleges that the manufacturers of both of these products were alerted starting in 2010 that there was an increased incidence of pancreatic cancer in users of these drugs as compared to diabetics treated with the older, more proven forms of treatment.   The notice also came from the German Medical Association and a petition by Public Citizen, a non-profit health group in Washington.

There have been similar reports of a sharp increase in pancreatitis—inflammation of the pancreas gland—in users of these same drugs.  The complaint alleges that pancreatitis may be a forerunner of pancreatic cancer.  Pancreatic cancer is among the deadliest of all cancers, for which there are no satisfactory treatments. 

The complaint charges that the defendants were aware of the serious health risks associated with the use of these drugs, and concealed them from the public, prescribing doctors and governmental regulatory bodies.  It not only seeks damages for the pain and suffering and economic loss sustained by the Cataletto family but also punitive or punishment damages based on "disregard for human life."

"From our examination of the data, it appears to us that there has been overpromotion and under warning by the sellers of these and other drugs in the incretin category," says Paul D. Rheingold, senior partner in the law firm.  The firm specializes in representing persons injured by drugs and medical devices."  It is currently heavily involved with litigation involving metal-on-metal hips made by DePuy and Stryker.

Attention is also being directed now to other drugs in the incretin category, including Victorza and Onglyza.  The manufacturers of all of these drugs announced in mid-June that they would cooperate with the Food and Drug Administration and the American Diabetes Association in studying the potential link between use of incretins and the development of pancreatic cancer. 

For more information please visit our website or contact our firm
Rheingold, Valet, Rheingold, McCartney & Giuffra LLP 
113 East 37th Street, New York, NY 10016  
Tel. No.:  1(800)349-0004/(212)684-1880


SOURCE Rheingold, Valet, Rheingold, Shkolnik & McCartney LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
2. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
3. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
6. Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
7. RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
8. Comments on The Nobel Prize Assemblys Response to the Lawsuit Filed by Life Scientist, Dr. Rongxiang Xu
9. China Nepstar Chain Drugstore Filed 2012 Annual Report on Form 20-F
10. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
11. Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):